PI Industries Limited Q4 Results 2026 Preview: Date, Time, Expectations & Key Things To Watch

PI Industries faces a critical quarter as it navigates a global agrochemical downturn and seeks to scale its emerging pharma CDMO business. Investors will be focused on whether the company can sustain its margin resilience despite demand softness and when its high-growth segments will regain momentum.

PI Industries Limited Q4 Results Date and Time

The board meeting is scheduled for May 19, 2026, to consider the audited financial results and recommend final dividend for FY 2025-26.

An earnings conference call is scheduled for May 20, 2026, at 3:00 PM IST to discuss the Q4 FY26 results.

What to expect from PI Industries Limited's Q4 FY26 results

In its most recently reported quarter, PI Industries posted revenue of Rs. 1,375.7 Cr, PAT of Rs. 311.3 Cr, and an EBITDA margin of 22%. The company is managing a challenging environment where exports declined 31% YoY in Q3 FY26 due to delivery schedule adjustments, while the domestic business faced a 7.9% YoY contraction. Management continues to prioritize its pharma CDMO expansion, targeting a revenue size 2 to 3 times larger in the next 3 to 4 years, even as the segment reported EBITDA losses of Rs. 195.6 Cr in FY25. With net working capital days increasing to 139 days from 115 days, the upcoming call will likely address the normalization of channel inventories and the resolution of regulatory restrictions impacting the domestic biologicals business.

Key Things To Watch

Performance vs Guidance Tracking: Tracking progress against management's stated FY26 targets.

• Revenue Growth: Mid-single digit target currently at risk following a 28% YoY decline in Q3
• EBITDA Margin: On track at 27% for 9MFY26 against a 25-26% target
• Pharma Growth: Challenging trajectory at 50% YoY over 9 months vs 75%+ target
• New Molecules: On track with 5 commercialized in Q3 against an 8-10 target

Strategic Updates: Operational milestones and business development progress.

• Commissioning status of two new multi-product plants (MPPs) expected to start by Q4 FY26 and Q1/Q2 FY27
• Resolution timeline for regulatory restrictions on the domestic biologicals business
• Registration progress for the first indigenous NCE, PIOXANILIPROLE

Operating Metric Trajectory: Key performance indicators for core and growth segments.

• Working capital management following the increase to 139 days in Q3 FY26
• Asset turns improvement trajectory currently at 1.47x against a 2.2-2.5x three-year target
• Pharma CDMO client onboarding and late-stage program pipeline (currently 6 programs in Phase I/II/III)